Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders. This Australian patent adds to the company's growing portfolio of intellectual property protections for its Klotho gene therapy platform, which is central to its biotech division's strategy. The patent's broad claims cover various aspects of gene therapy, including constructs and delivery systems, which could provide a competitive advantage in the development of treatments for ALS and similar conditions.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: Mining and Biotech. The Mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland. The Biotech division includes Klotho’s KLTO‑202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The granting of this patent is a significant milestone for Greenland Mines' biotech division, as it provides stronger legal protection for its gene therapy technology in Australia, a key market. The company's KLTO-202 program is designed to address ALS, a devastating neurodegenerative disease with limited treatment options. By securing patent protection, Greenland Mines may be better positioned to advance its clinical development and potential commercialization efforts.
For more information, the full press release is available at https://nnw.fm/PVbbH. The latest news and updates relating to GRML are available in the company’s newsroom at https://nnw.fm/GRML.
